Abstract P87: Drug-induced Hyperactivation of the oncogene KRAS induces ferroptosis in G12-mutant KRAS Pancreatic Ductal Adenocarcinoma (PDAC)
C1 is presented as a novel therapeutic agent for KRAS-mutant PDAC and the concept of hyperactivating oncogenic KRAS to selectively induce ferroptotic cancer cell death is introduced.